Chris Parker
@PCaParker
Prostate oncologist, cyclist, would-be climate activist
Hi friends, it's #ProstateCancer Friday. Here are Top Posts of the Week! 🎉🎉🎉 1/ @TylerSbrt on active surveillance failure in prostate cancer: x.com/TylerSbrt/stat…
Brief 🧵 1/ How common is *failure* of modern active surveillance (AS) for #ProstateCancer (PCa)? Which patients are at higher risk? Spoiler 🚨: it’s pretty simple @EurUrolOncol @UroToday @OncoAlert @PCF_Science @gu_onc @AmerUrological @Uroweb
Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 sciencedirect.com/science/articl… The Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where…
Brief 🧵 1/ How common is *failure* of modern active surveillance (AS) for #ProstateCancer (PCa)? Which patients are at higher risk? Spoiler 🚨: it’s pretty simple @EurUrolOncol @UroToday @OncoAlert @PCF_Science @gu_onc @AmerUrological @Uroweb
Advocates suggest administrative real-world data can substitute for #RCTs and offer propensity matching to reduce bias. But results often fail to correspond: #BMJ study showed direction of effect differed in 31% & CI failed to include #RCT estimate in 56% pubmed.ncbi.nlm.nih.gov/26858277/
Online: Metformin for patients with metastatic #prostatecancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol @Silke_Gillessen, @Prof_Nick_James, @AshwinUrol, and colleagues thelancet.com/journals/lanon…
Would be really helpful to be able to generate individualised estimates of MFS/PCSS/OS for salvage RT alone (beyond the subgroup data from Supp Table 4). Any plans for a nomogram/calculator, or suggestions re how to go about this? #radonc #pcsm
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/articl… This systematic review and meta-analysis by the DADSPORT Collaboration…
New review led by @DeepOnco of @royalmarsdenNHS outlines global trends and evolving diagnostics, treatment, and surveillance of #ProstateCancer. Read: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @PCaParker @AmarUKishan @VedangMurthy @nickva1 @alison_tree @APCCC_Lugano @ICR_London
Delighted to share our comprehensive review on #ProstateCancer, now out in @CACancerJournal , the highest-impact STEM journal. Huge thanks to an amazing team ! @alison_tree @PCaParker @AmarUKishan @VedangMurthy @nickva1 @royalmarsdenNHS @ICR_London Link: doi.org/10.3322/caac.7…
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/articl… This systematic review and meta-analysis by the DADSPORT Collaboration…
🛑A meta-analysis from the DADSPORT Collaboration: Adding hormone therapy to post-op radiotherapy in nonmetastatic prostate cancer improves: ✅ Metastasis-free survival (HR=0.78) ✅ Prostate cancer–specific survival (HR=0.61) 📉 Overall survival benefit small (HR=0.86), limited…
Another trial pointing at MMR defects as biomarker of ICI sensitivity in prostate cancer. Read ⬇️ @RMresearch_ @FenorLolin @AdamSharpMedOnc thank you to all the ICR team and Prof De Bono for this 💪🏻
🚨Epidemiology of High-risk Biochemical Recurrence After Primary #ProstateCancer Treatment🚨 🙍♂️🙍♂️17K population-based study 👉 Using BCR risk groups continues to show promise to personalize treatment intensity for future patients @EurUrolOncol 🔗shorturl.at/LuvYZ…
Assisted dying is an existential choice, not a treatment bmj.com/content/389/bm…
Palliative Care and what it does. My piece in @spectator today
Recent heated debates may have left some with the impression that most deaths in the UK are bad, that palliative care cannot do anything and that hospices are ghoulish places that only give morphine infusions. Think opium den, just with doctors and nurses. This is completely…
Beautifully written. @ProfMarkTaubert 🙏🏻
Palliative care is "only a little bit about dying. Let’s call it assisted living." @ProfMarkTaubert spectator.co.uk/article/the-tr…
Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. ja.ma/45rVOSb @IvoSchootsNL
Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology Full-text authors.elsevier.com/a/1lFrI3lXQoc1… @HarshaniGreen @alison_tree @royalmarsdenNHS @ICR_London @ElsevierConnect @OncologyAdvance
Want to work in the cutting edge Uro-oncology unit at the Royal Marsden? An opportunity to work with #alisontree, #chrisparker, #shaistahafeez, #juliamurray among others. We are looking for TWO clinical oncologists to join us. Link to application below
It remains disappointing that (unlike the Lu-PSMA trials) the #PARP inhibitor trials do not include cross over and thus continue to leave the key question of sequence unanswered. This limits understanding of clinical optimization #AMPLITUDE #ASCO25 @asco
As new #mCSPC #PFS data is unveiled w/#PARP & Lu-PSMA it is worth nothing all previous mCSPC trials showed OS despite large functional cross overs Did we lower standard to PFS when both agents are approved for mCRPC? 🤔 #ProstateCancer #ASCO25 nature.com/articles/s4158…
Impressive data, especially for pts with BRCAm, but in mHSPC, for once not in RCC. Sorry, Tom! Compliments to @AttardLab and team!
AMPLITUDE trial #ASCO25 @AttardLab @OncoAlert increases rPFS for niraparib (PARPi) + ARPI (Abi) in mCSPC with + BRCA/HRR (HR-0.53/0.63) & a trend toward improved OS (HR0.75/0.79). This moves PARPi into 1st line and supports personalised approaches in 1st line RCC